Literature DB >> 33685417

A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy.

Dongdong Zhou1, Xiaoli Liu1, Xinhui Wang1, Fengna Yan1, Peng Wang1, Huiwen Yan1,2, Yuyong Jiang1, Zhiyun Yang3.   

Abstract

BACKGROUND: Alpha-fetoprotein-negative hepatocellular carcinoma (AFP-NHCC) (< 8.78 ng/mL) have special clinicopathologic characteristics and prognosis. The aim of this study was to apply a new method to establish and validate a new model for predicting the prognosis of patients with AFP-NHCC.
METHODS: A total of 410 AFP-negative patients with clinical diagnosed with HCC following non-surgical therapy as a primary cohort; 148 patients with AFP-NHCC following non-surgical therapy as an independent validation cohort. In primary cohort, independent factors for overall survival (OS) by LASSO Cox regression were all contained into the nomogram1; by Forward Stepwise Cox regression were all contained into the nomogram2. Nomograms performance and discriminative power were assessed with concordance index (C-index) values, area under curve (AUC), Calibration curve and decision curve analyses (DCA). The results were validated in the validation cohort.
RESULTS: The C-index of nomogram1was 0.708 (95%CI: 0.673-0.743), which was superior to nomogram2 (0.706) and traditional modes (0.606-0.629). The AUC of nomogram1 was 0.736 (95%CI: 0.690-0.778). In the validation cohort, the nomogram1 still gave good discrimination (C-index: 0.752, 95%CI: 0.691-0.813; AUC: 0.784, 95%CI: 0.709-0.847). The calibration curve for probability of OS showed good homogeneity between prediction by nomogram1 and actual observation. DCA demonstrated that nomogram1 was clinically useful. Moreover, patients were divided into three distinct risk groups for OS by the nomogram1: low-risk group, middle-risk group and high-risk group, respectively.
CONCLUSIONS: Novel nomogram based on LASSO Cox regression presents more accurate and useful prognostic prediction for patients with AFP-NHCC following non-surgical therapy. This model could help patients with AFP-NHCC following non-surgical therapy facilitate a personalized prognostic evaluation.

Entities:  

Keywords:  Alpha-fetoprotein-negative hepatocellular carcinoma; LASSO cox regression; Nomogram; Non-surgical therapy; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 33685417      PMCID: PMC7938545          DOI: 10.1186/s12885-021-07916-3

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  55 in total

Review 1.  Management of hepatocellular carcinoma with portal vein thrombosis.

Authors:  Matthew Quirk; Yun Hwan Kim; Sammy Saab; Edward Wolfgang Lee
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma.

Authors:  Seong K Na; Sun Y Yim; Sang J Suh; Young K Jung; Ji H Kim; Yeon S Seo; Hyung J Yim; Jong E Yeon; Kwan S Byun; Soon H Um
Journal:  J Surg Oncol       Date:  2018-02-15       Impact factor: 3.454

3.  Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma.

Authors:  Jae Min Chun; Hyung Jun Kwon; Junho Sohn; Sang Geol Kim; Ji-Young Park; Han Ik Bae; Young Kook Yun; Yoon Jin Hwang
Journal:  J Surg Oncol       Date:  2010-12-22       Impact factor: 3.454

Review 4.  Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis.

Authors:  An Tang; Oussama Hallouch; Victoria Chernyak; Aya Kamaya; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2018-01

5.  Ductular reaction, cytokeratin 7 positivity, and gamma-glutamyl transferase in multistage hepatocarcinogenesis in rats.

Authors:  Andrea Janz Moreira; Graziella Ramos Rodrigues; Silvia Bona; Leila Xavier Sinigaglia Fratta; Giovana Regina Weber; Jaqueline Nascimento Picada; Jorge Luiz Dos Santos; Carlos Thadeu Cerski; Claudio Augusto Marroni; Norma Possa Marroni
Journal:  Protoplasma       Date:  2016-08-15       Impact factor: 3.356

Review 6.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

Review 7.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

8.  Ultrasound and cone beam CT fusion for liver ablation: technical note.

Authors:  Lorenzo Monfardini; Franco Orsi; Rosalba Caserta; Claudio Sallemi; Paolo Della Vigna; Guido Bonomo; Gianluca Varano; Luigi Solbiati; Giovanni Mauri
Journal:  Int J Hyperthermia       Date:  2018-09-11       Impact factor: 3.914

9.  Impact of gender as a prognostic factor in HBV-related Hepatocellular Carcinoma: the survival strength of female patients in BCLC stage 0-B.

Authors:  Lihua Yu; Xiaoli Liu; Xinhui Wang; Zhibo Dang; Yuyong Jiang; Xianbo Wang; Zhiyun Yang
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

10.  Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases.

Authors:  Salvatore Petta; Fabio Salvatore Macaluso; Maria Rosa Barcellona; Calogero Cammà; Daniela Cabibi; Vito Di Marco; Antonio Craxì
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more
  1 in total

1.  Identification of key genes associated with esophageal adenocarcinoma based on bioinformatics analysis.

Authors:  Weifeng Qi; Rongyang Li; Lin Li; Shuhai Li; Huiying Zhang; Hui Tian
Journal:  Ann Transl Med       Date:  2021-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.